Head Trauma |
Trauma is a leading cause of death in children older than 1 year in the United States, with head trauma representing 80% or more of the injuries. Approximately 5% of head trauma victims die at the site of the accident. Head trauma has a high emotional, psychosocial, and economic impact as these patients often have comparatively long hospital stays, and 5-10% require discharge to a long-term care facility.
The anatomical differences of the child's brain render it more susceptible than an adult's to certain type of injuries following head trauma. The head is larger in proportion to the body surface area, and stability is dependent on the ligamentous rather than bony structure. The pediatric brain has a higher water content, 88% vs 77% in adult, which makes the brain softer and more prone to acceleration-deceleration injury. The water content is inversely related to the myelinization process. The unmyelinated brain is more susceptible to shear injuries. Infants and young children tolerate intracranial pressure (ICP) increases better because of open sutures .
Pathophysiology: Primary and secondary injuries are described with head trauma, and their presence affect. the outcome of these patients.
The primary injury occurs at the time of impact, either by a direct injury to the brain parenchyma or by an injury to the long white-matter tracts through acceleration-deceleration forces. Direct injury to the brain parenchyma occurs as the brain is impacted on the bony protuberances of the calvarium or by penetration of the brain by bony fragments or a foreign body. In children, the compliant skull is easily deformed, and impacts on the brain at the time of the insult result in a coup injury, as opposed to adults, in whom the brain is forced against the bony protuberances opposite the point of the impact, resulting in a countercoup injury. Intracranial hemorrhage also may result from shearing or laceration of vascular structures. Acceleration-deceleration forces cause shearing of the long white-matter tracts, leading to axonal disruption and secondary cell death.
The secondary injury is represented by systemic and intracranial events that occur in response to the primary injury and further contribute to neuronal damage and cell death.
The systemic events are hypotension, hypoxia, and hypercapnia and may occur as a direct result of primary injury to the CNS or could result from associated injuries in a person with multiple traumas.
The intracranial events are a series of inflammatory changes and pathophysiologic perturbations that occur immediately after the primary injury and continue over time. Their presence adds to the adverse outcome of the head trauma patient. The inflammatory events are the result of a cascade of biomolecular changes triggered by the initial insult leading to microcirculatory disruption and neuronal disintegration. A series of factors such as free radicals, free iron, and excitatory neurotransmitters (glutamate, aspartate) are the result of these inflammatory events, and their presence contributes to the negative outcome. The pathophysiologic events, are cerebral edema, ICP, hyperemia, and ischemia.
The brain has minimal ability to store energy thus it is dependent on aerobic metabolism. The delivery of oxygen and metabolic substrate to the brain is maintained by a constant supply of blood known as cerebral blood flow. Cerebral blood flow (CBF) defined as the amount of blood in transit through the brain at one given point in time is estimated to be in a normal adult 50/ml/100g/min, and is known to be much higher in children. The minimum amount necessary to prevent ischemia however remains unknown. CBF is influenced by mean arterial blood pressure (MAP), ICP, viscosity of the blood, metabolic products, and the diameter of brain vessels. CBF should not be confused with cerebral blood volume (CBV), which represents the amount of blood present in the brain vasculature. CBV is the major contributor to the ICP and is dependent on the diameter of intracranial vessels. When CBV is increased, the pressure gradient across the compartment is decreased, and the CBF is decreased.
The brain has the capacity of maintaining constant blood flow, through a mechanism known as autoregulation. This occurs over a wide range of blood pressures through changes in cerebral resistance in response to fluctuations in MAP pressure. It is established that the CBF is maintained between a MAP of 60-150 mmHg. At 60 mmHg the cerebral vasculature is maximally dilated and at 150 mmHg is maximally constricted. Fluctuations past this range will lead to alterations in CBF and contribute to ischemia or disruption of the blood-brain barrier. Several mechanisms are known to affect autoregulation of CBF, and they can be divided in metabolic products and arterial blood gas content, myogenic, neurogenic, and endothelium-dependent factors. Their effect is not fully known and their mechanism of action is still under experimental investigation.
CBF is closely linked to cerebral metabolism. Although the mechanism of coupling is not clearly defined it is suspected to involve vasodilators released from neurons. Several factors have been implicated such as adenosine and free radicals. Pathophysiologic states such as fever, seizure activity known to increase the metabolic activity will lead to an increase in CBF.
CBF can be altered by changes in the partial pressure of oxygen or carbon dioxide. Alteration in the partial pressure of oxygen acts on the vascular smooth muscle through mechanisms that remained unclear. Hypoxia causes vasodilatation with significant increase in CBF. Increases in oxygen pressure cause vasoconstriction but to a lesser degree than hypoxia. Hypercarbia increases CBF up to 350% of normal, hypocapnia produces a decrease in blood flow. The mechanism appears to involve alteration in tissue pH that leads to changes in arteriolar diameter. This mechanism is preserved even when autoregulation is lost.
The myogenic mechanism was considered for a long time to be the most important in the autoregulation process. It was thought that the changes in the actin-myosin complex lead to rapid changes in the vasculature diameter thus affecting the CBF. Currently it has been shown that it mostly causes dampening of arterial pulsation and has little direct effect on cerebral autoregulation.
The neurogenic mechanism is represented by the effect of the sympathetic system on the cerebral vasculature. The sympathetic nervous system shifts autoregulation towards higher pressures whereas sympathetic blockade shifts it downwards.
Recent studies identified nitric oxide as one of the factors affecting cerebral autoregulation by producing relaxation of cerebral vessels. It is present in several conditions such as ischemia, hypoxia, and stroke. Nitric oxide has been shown to be generated by different cells at rest but also under direct stimulation by factors like cytokines.
Traumatic brain injury may lead to loss of autoregulation through alterations of the described mechanisms. These mechanisms represent the foundation upon which the medical management of increased ICP and cerebral perfusion pressure is based in patients with traumatic brain injury.
Frequency:
Mortality/Morbidity: The overall outcome for children with head injuries is better than that of adults with the same injury score. Recovery in children takes longer, from months to, sometimes, years, whereas adults reach maximum recovery by about 6 months following the injury. Outcome assessment based on Glasgow Coma Scale (GCS) could be used as an early predictor but has limitations regarding long-term outcome. Victims of multiple organ injuries, including head trauma, generally have a far worse outcome than those with isolated head injury alone.
Race: African American adolescent boys account for most of the firearms-related CNS injuries in pediatric population.
Sex: Males are twice as likely to sustain head injuries than females and have 4 times the risk of fatal trauma.
Age: The distribution of head trauma is relatively stable throughout childhood. An increase in the incidence of head trauma was identified in 2 age groups.
History: Head trauma patients may experience one or a combination of primary injuries, depending on the degree and mechanism of trauma. Specific types of primary injury include scalp injury, skull fracture, basilar skull fracture, concussion, contusion, intracranial hemorrhage, subarachnoid hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, penetrating injuries, and diffuse axonal injury.
Physical: Head trauma patients often have multiple organ injuries. Assessment of patients with severe head injuries involves a primary and a secondary survey. The primary survey is a focused physical exam directed at identifying and treating life-threatening conditions present in a trauma patient and by this, preventing secondary brain injury. The secondary survey of patients with head trauma is a detailed examination and assessment of the system with the goal of identifying all traumatic injuries and directing further treatment.
Table 1. Eye Opening
³1 Year | 0-1 Year |
---|---|
4 Spontaneously | Spontaneously |
3 To verbal command | To shout |
2 To pain | To pain |
1 No response | No response |
³1 Year | 0-1 Year |
---|---|
6 Obeys command | |
5 Localizes pain | Localizes pain |
4 Flexion withdrawal | Flexion withdrawal |
3 Flexion abnormal (decorticate) | Flexion abnormal (decorticate) |
2 Extension (decerebrate) | Extension (decerebrate) |
1 No response | No response |
>5 Years | 2-5 Years | 0-2 YEARS |
---|---|---|
5 Oriented and converses | Appropriate words | Cries appropriately |
4 Disoriented and converses | Inappropriate words | Cries |
3 Inappropriate words | Cries / Screams | Inappropriate crying / scream |
2 Incomprehensible sounds | Grunts | Grunts |
1 No response | No response | No response |
Causes: Most head injuries occur secondary to motor vehicle accidents, falls, assaults, recreational activities, and child abuse. The percentage of each contributing factor differs between studies, and the distribution varies according to age group and sex. Few factors such as seizure disorder, attention deficit disorder, and alcohol and drug use enhance the vulnerability of the child or adolescent to this type of trauma. Infants and young children are more vulnerable to abuse because of their dependency on adults.
Lab Studies:
Imaging Studies:
Other Tests:
Procedures:
Medical Care: The goal of medical care of patients with head trauma is to recognize and treat life-threatening conditions and to eliminate or minimize the role of secondary injury. Patients with severe head trauma are at increased risk of developing cerebral edema, respiratory failure, and herniation secondary to the increased ICP; therefore, frequent serial assessments of the neurologic status must be performed.
The Brain Trauma Foundation has developed guidelines regarding the medical management of patients with severe head injury. These guidelines suggest that cardiopulmonary resuscitation should be the foundation upon which treatment of intracranial hypertension must be based. They also state that in the absence of any obvious signs of increased ICP no prophylactic treatment should be initiated as this may directly interfere with the optimal resuscitation process.
Surgical Care:
Consultations:
Diet: Nutritional support is directed at avoiding hypoglycemia or hyperglycemia and providing enough calories to prevent catabolism and a negative nitrogen balance. Either enteral or parenteral route could be used, depending on the clinical status of the patient.
Activity:
Medical therapy is
directed at controlling the ICP with sedatives and neuromuscular blockers,
diuretics, lidocaine, and anticonvulsants.
Drug Category: Nondepolarizing neuromuscular blockers -- These are used in combination with a sedative as part of the rapid sequence intubation process or to achieve control of the ICP.
Drug Name |
Vecuronium (Norcuron) -- Used to facilitate endotracheal intubation and provide neuromuscular relaxation during the intubation and mechanical ventilation. Used as an adjunct to a sedative or hypnotic agent. | ||||||||
---|---|---|---|---|---|---|---|---|---|
Adult Dose | 0.1 mg/kg/dose IV | ||||||||
Pediatric Dose | Loading dose: 0.08-0.1 mg/kg/dose
IV Maintenance: 0.05-0.1 mg/kg/dose IV q1h prn; alternatively, 0.1 mg/kg/h IV as continuous infusion Contraindications |
Documented hypersensitivity; myasthenia
gravis or related syndromes
| Interactions |
When vecuronium is used concurrently with
inhalational anesthetics, neuromuscular blockade is enhanced; renal or
hepatic failure as well as concomitant administration of steroids may
result in prolonged blockade despite withdrawal of the agent
| Pregnancy |
C - Safety for use during pregnancy has
not been established.
| Precautions |
Smaller dose should be used in patients
with myasthenia gravis and the effect titrated with a peripheral nerve
stimulator | |
Drug Name |
Thiopental (Pentothal Sodium) -- DOC for
endotracheal intubation of patients with head injury. Also decreases the
ICP. Facilitates, transmission or impulses from thalamus to cortex of brain, resulting in an imbalance in central inhibitory and facilitatory mechanisms. Adult Dose |
75-250 mg/dose IV, repeat prn
| Pediatric Dose |
Induction: 4-6 mg/kg/dose
IV | Maintenance: 1 mg/kg IV prn 1.5-5 mg/kg/dose IV is used to treat acute rises in the ICP Contraindications |
Documented hypersensitivity; porphyria;
presence of severe hypovolemia or unstable hemodynamics; lack of
familiarity with drug; inability to manage airway
| Interactions |
Coadministration with CNS depressants,
salicylates, sulfisoxazole, increases toxicity
| Pregnancy |
C - Safety for use during pregnancy has
not been established.
| Precautions |
May cause myocardial depression,
decreased cardiac output, and hypotension; caution in hepatic or renal
insufficiency, asthma, severe cardiovascular disease, unstable aneurysm,
hypotension, laryngospasm or bronchospasm | |
---|
Drug Name |
Pentobarbital (Nembutal) -- Short-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. May be used in high dosage to induce barbiturate coma for treatment of refractory increased ICP. | ||||||||
---|---|---|---|---|---|---|---|---|---|
Pediatric Dose | Pentobarbital coma: Loading dose: 10-15 mg/kg/dose IV over 1-2 h Maintenance: 1 mg/kg/h IV; may increase to 2-3 mg/kg/h until burst suppression is shown on EEG Contraindications |
Documented hypersensitivity; liver
failure
| Interactions |
Concomitant use with alcohol may produce
additive CNS effects and fatality; chloramphenicol may inhibit
pentobarbital metabolism; pentobarbital may enhance chloramphenicol
metabolism; MAOIs may enhance sedative effects of barbiturates; valproic
acid appears to decrease barbiturate metabolism, increasing toxicity;
barbiturates can decrease effects of anticoagulants (patients may require
dosage adjustments if barbiturates added to or withdrawn from regimen);
barbiturates may decrease corticosteroid and digitoxin effects through
induction of hepatic microsomal enzymes, which increase metabolism;
barbiturates decrease theophylline levels, and may decrease effects;
pentobarbital may decrease verapamil bioavailability
| Pregnancy |
D - Unsafe in pregnancy
| Precautions |
Rapid and prolonged IV administration may
cause hypotension, respiratory depression, apnea, bronchospasm, and
laryngospasm; caution in hypovolemic shock, respiratory dysfunction, renal
dysfunction, and congestive heart failure | |
Drug Name |
Phenobarbital (Luminal, Solfoton) -- Used for seizure control in patients with head trauma . | ||||||||
---|---|---|---|---|---|---|---|---|---|
Adult Dose | 300-800 mg, followed by 120-240 mg/dose at 20-min intervals until seizures are controlled or total dose of 1-2 g is administered | ||||||||
Pediatric Dose | Loading dose: 15-20 mg/kg/dose IV in
single or divided doses Maintenance: 5 mg/kg/d PO/IV divided bid Contraindications |
Documented hypersensitivity; severe
respiratory disease, marked impairment of liver function, and nephritis
| Interactions |
May decrease effects of chloramphenicol,
digitoxin, corticosteroids, carbamazepine, theophylline, verapamil,
metronidazole, and anticoagulants (patients stabilized with anticoagulants
may require dosage adjustments if added to or withdrawn from their
regimen); coadministration with alcohol may produce additive CNS effects
and death; chloramphenicol, valproic acid, and MAOIs may increase
phenobarbital toxicity; rifampin may decrease phenobarbital effects
| Pregnancy |
D - Unsafe in pregnancy
| Precautions |
Monitor respiratory and cardiac function
during loading dose; may cause drowsiness and impaired ability to perform
tasks requiring alertness; caution in myasthenia gravis and
myxedema | |
Drug Name |
Midazolam (Versed) -- Short-acting benzodiazepine with rapid onset of action. Useful in treating increased ICP. |
---|---|
Pediatric Dose | 0.05-0.1 mg/kg/dose IV; dose may be repeated prn; not to exceed a cumulative dose of 6 mg for infants and 10 mg for children |
Contraindications | Documented hypersensitivity; uncontrolled pain; preexisting hypotension, narrow-angle glaucoma |
Interactions | Sedative effects of midazolam may be antagonized by theophyllines; narcotics and erythromycin may accentuate sedative effects of midazolam because of decreased clearance |
Pregnancy | D - Unsafe in pregnancy |
Precautions | Careful monitoring of cardiorespiratory status during administration; caution in congestive heart failure, pulmonary disease, renal impairment, and hepatic failure |
Drug Name |
Lorazepam (Ativan) -- Long-acting benzodiazepine, used as anticonvulsant for immediate control of seizure activity. |
---|---|
Adult Dose | 4 mg/dose IV slowly over 2-5 min and repeat in 10-15 min prn; not to exceed a cumulative dose of 8 mg/12 h |
Pediatric Dose | 0.05-0.1 mg/kg/dose IV over 2-5 min; may be repeated in 10-15 min |
Contraindications | Documented hypersensitivity; preexisting CNS depression, hypotension, and narrow-angle glaucoma; uncontrolled pain |
Interactions | Toxicity of benzodiazepines in CNS increases when used concurrently with alcohol, phenothiazines, barbiturates, and MAOIs |
Pregnancy | D - Unsafe in pregnancy |
Precautions | Cardiorespiratory monitoring during administration is required; long-term use requires liver function and CBC monitoring; caution in renal or hepatic impairment, myasthenia gravis, organic brain syndrome, or Parkinson disease |
Drug Name |
Phenytoin (Dilantin) -- May act in motor cortex where may inhibit spread of seizure activity. Activity of brain stem centers responsible for tonic phase of grand mal seizures also may be inhibited. Is preferred to phenobarbital to control seizures because it does not cause as much CNS depression. | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Adult Dose | Loading dose for status epilepticus:
15-20 mg/kg PO/IV once or in divided doses, followed by 100-150 mg/dose at
30-min intervals Initial maintenance dose (administered 12 h after loading dose): 100 mg (use 125 mg for oral susp) IV/PO tid Maintenance: 300-400 mg/d PO/IV divided tid, or qd/bid if using ER; increase to 600 mg/d (625 mg/d for oral susp) may be necessary; do not exceed 1500 mg/24h Rate of IV infusion must not exceed 50 mg/min to avoid hypotension and arrhythmias Pediatric Dose |
Loading dose: 15-20 mg/kg PO/IV once or
in divided doses | Initial maintenance dose (administered 12 h after loading dose): 5 mg/kg/d PO/IV divided bid/tid Maintenance: 4-8 mg/kg PO/IV divided bid/tid >6 years: May require minimum adult dose (300 mg/d); not to exceed 300 mg/d Contraindications |
Documented hypersensitivity; sinoatrial
block, second- and third-degree AV block, sinus bradycardia, or
Adams-Stokes syndrome
| Interactions |
Amiodarone, benzodiazepines,
chloramphenicol, cimetidine, fluconazole, isoniazid, metronidazole,
miconazole, phenylbutazone, succinimides, sulfonamides, omeprazole,
phenacemide, disulfiram, ethanol (acute ingestion), trimethoprim, and
valproic acid may increase phenytoin toxicity | Phenytoin effects may decrease when taken concurrently with barbiturates, diazoxide, ethanol (chronic ingestion), rifampin, antacids, charcoal, carbamazepine, theophylline, and sucralfate Phenytoin may decrease effects of acetaminophen, corticosteroids, dicumarol, disopyramide, doxycycline, estrogens, haloperidol, amiodarone, carbamazepine, cardiac glycosides, quinidine, theophylline, methadone, metyrapone, mexiletine, oral contraceptives, valproic acid Continuous tube feeding decreases the bioavailability of phenytoin Pregnancy |
D - Unsafe in pregnancy
| Precautions |
Perform blood counts and urinalyses when
therapy is initiated; discontinue use if a rash appears and do not resume
use if rash is exfoliative, bullous or purpuric; rapid IV infusion may
result in death from cardiac arrest, marked by QRS widening; caution in
acute intermittent porphyria and diabetes (may elevate blood sugars);
discontinue use if hepatic dysfunction occurs | |
Drug Name |
Furosemide (Lasix) -- A loop diuretic
helpful in decreasing the ICP via 2 mechanisms. One influences CSF
formation by affecting the sodium-water movement across the blood-brain
barrier; the other mechanism is the preferential excretion of water over
solute in the distal tubule. Mostly useful when used in combination with mannitol, especially when the latter is administered 15 min before furosemide. Adult Dose |
20-80 mg/d IV/IM; may increase dose; not
to exceed 600 mg/d
| Pediatric Dose |
1-2 mg/kg/dose IV q6-12h
| Contraindications |
Documented hypersensitivity; hepatic
coma, anuria, and severe electrolyte depletion
| Interactions |
Metformin decreases furosemide
concentrations; furosemide interferes with hypoglycemic effect of
antidiabetic agents and antagonizes muscle relaxing effect of
tubocurarine; auditory toxicity appears to be increased with
coadministration of aminoglycosides and furosemide; hearing loss of
varying degrees may occur; anticoagulant activity of warfarin may be
enhanced when taken concurrently with this medication; increased plasma
lithium levels and toxicity are possible when taken concurrently with this
medication
| Pregnancy |
C - Safety for use during pregnancy has
not been established.
| Precautions |
Avoid hypotension due to large volume
depletion; requires serum electrolyte monitoring | |
---|
Drug Name |
Mannitol (Osmitrol) -- Osmotic diuretic, which lowers the blood viscosity and produces cerebral vasoconstriction with normal cerebral blood flow. ICP decrease occurs subsequent to a decrease in cerebral blood volume. | ||||||||
---|---|---|---|---|---|---|---|---|---|
Adult Dose | 1.5-2 g/kg IV as 20% solution (7.5-10 mL/kg) or as 15% solution (10-13 mL/kg) over a period as short as 30 min | ||||||||
Pediatric Dose | 0.5-1 g/kg/dose IV initial
dose 0.25-0.5 g/kg/dose IV q4-6h Contraindications |
Documented hypersensitivity; anuria,
severe pulmonary congestion, progressive renal damage, severe dehydration,
active intracranial bleeding, and progressive heart failure
| Interactions |
May decrease serum lithium levels
| Pregnancy |
C - Safety for use during pregnancy has
not been established.
| Precautions |
Carefully evaluate cardiovascular status
before rapid administration of mannitol because a sudden increase in
extracellular fluid may lead to fulminating CHF; avoid
pseudoagglutination, when blood given simultaneously, add at least 20 mEq
of sodium chloride to each liter of mannitol solution; do not give
electrolyte-free mannitol solutions with blood; If used every 4-6 h, serum
osmolarity should be monitored and dose held if osmolarity exceeds 320
mOsm/kg | |
Drug Name |
Lidocaine 1% (Xylocaine) -- Used with good results in controlling the ICP in patients with head trauma. |
---|---|
Pediatric Dose | 1-1.5 mg/kg/dose IV |
Contraindications | Documented hypersensitivity to amide-type local anesthetics; avoid in Adams-Stokes syndrome and Wolf-Parkinson-White syndrome; avoid in severe sinoatrial, atrioventricular (AV), or intraventricular block, if artificial pacemaker not in place |
Interactions | Coadministration with cimetidine or beta-blockers, increases toxicity of lidocaine; coadministration with procainamide and tocainide may result in additive cardiodepressant action; may increase effects of succinylcholine |
Pregnancy | B - Usually safe but benefits must outweigh the risks. |
Precautions | Caution in heart failure, hepatic disease, hypoxia, hypovolemia or shock, respiratory-depression and bradycardia; may increase risk of CNS and cardiac adverse effects in elderly patients; high plasma concentrations can cause seizures, heart block, and AV conduction abnormalities |
Further Inpatient Care:
Further Outpatient Care:
In/Out Patient Meds:
Transfer:
Deterrence/Prevention:
Complications:
Prognosis:
Patient Education:
Medical/Legal Pitfalls:
Home page, Drug information's ,Regional anesthesia ,Index for diseases ,Index for diseases, Perioperative medicine, Search engine, Accreditation, Learn Arabic Warfare, Anesthesia LINKS, Orthopedic LINKS, Midline
Constructed by Dr N.A. Nematallah Consultant in perioperative medicine and intensive therapy, Al Razi Orthopedic Hospital , State of Kuwait, email : razianesth@freeservers.com